Identification of key genes with clinical outcome in benign meningioma using bioinformatic analysis

Ming Cao a, Chen Shen a*, Jie Zhu a, YuHai Wang a**
904st Hospital of PLA (WuXi TaiHu Hospital), Department of Neurosurgery, Wuxi, China
* Co first author, Chen Shen, E-mail: shene904@163.com
** Corresponding author, YuHai Wang, E-mail: mwyh904@163.com

ABSTRACT

Background: Meningioma is the second most common type of brain neoplasms. However, the underlying molecular mechanisms are still not clear, and the main treatment is mainly surgery plus radiotherapy.

Material and method: To explore the key genes in benign meningioma, we downloaded microarray dataset GSE43290 from Gene Expression Omnibus (GEO) database. The differential genes (DEGs) between benign meningioma and normal meninges were identified by GEO2R. The gene ontology (GO) and Kyoto Encyclopedia of Gene and Genomes (KEGG) pathway were performed by the Database for Annotation, Visualization and Integrated Discovery (DAVID). The protein-protein interaction (PPI) network and module analysis were performed and visualized by the Search Tool for the Retrieval of Interacting Gene database (STRING) and Cytoscape. The hub genes were evaluated by the Cytohubba and further explored by MCODE plugin of Cytoscape and Enrichr. The relationship between hub genes and clinical factors were further explored by GSE16581 through R software.

Result: A total of 358 DEGs were identified, including 15 upregulated genes and 343 downregulated genes. The main enriched functions were extracellular matrix organization, inflammatory response, cell adhesion, extracellular space and integrin binding. The main KEGG pathways were Malaria and focal adhesion. Among these DEGs, 5 overlapping genes (CXCL8, AGT, CXCL2, CXCL12, CXCR4) were selected as hub genes. CXCL2 and CXCL8 were correlated with age and tumor recurrence, which could be clinical therapeutic targets.

Conclusion: This study indicates the key genes in benign meningioma which may help us understand the molecular mechanisms and provide the candidate therapeutic targets.

Keywords: meningioma; GEO data; hub gene; bioinformatic analysis.

1. Background

Meningioma, originating from arachnoid meningiothelial cells, is the second most common neoplasm in central nervous system, accounting for approximately 30% of newly diagnosed CNS tumors. In 2016 WHO classification of CNS tumors, meningiomas were classified into three types: I, II, III, and the grade I meningiomas belong to typical/benign meningiomas, approximately equaling to...
88-94% of all meningiomas\textsuperscript{[1-3]}. The median diagnosed age is 65 years, the atypical or anaplastic meningiomas often occurring in elderly people than younger group, and the ratio of female to male is 2.2:1\textsuperscript{[4]}. The primary diagnosis of suspected meningioma is mostly based on magnetic resonance imaging (MRI), which could probably distinguish benign from atypical meningioma\textsuperscript{[5,6]}. The pathological diagnosis is the golden standard, but histological diagnosis wouldn’t explain the reason that benign meningioma shows signs of malignant proliferation or long-distance metastasis\textsuperscript{[6]}. With advanced molecular profiling technology, we could define the most significant two type of meningioma: a group of tumors with neurofibromatosis 2 mutations which tend to be atypical or anaplastic pathologies, and meningiomas with non-NF2 mutations which tend to be benign pathology, including TRAF7, KLF4, SMO, AKT1, POLR2A\textsuperscript{[7, 8]}. But those mutational analysis alone couldn’t help clinical conditions which patients need follow-up or alternative therapies.

The most important therapy for meningioma is surgical resection. Some researches reported that patients undergoing Simpson Grade I resection showed lower risk of recurrence than those with Simpson Grade II-IV resection, and besides high-grade WHO lesions, advanced sinus invasion, high Ki-67 expression and MIB index >3% were significantly associated with a higher risk of recurrence\textsuperscript{[9, 10, 11]}. Patients who only underwent subtotal resection had a higher risk of recurrence than those undergoing surgical resection and post-operative radiotherapy\textsuperscript{[12-14]}. But as we all know, radiation was strongly associated with higher risk of meningioma, radiotherapy could induce treatment-related side effects and long-term toxicity, including inducing malignant transformation\textsuperscript{[10-17]}. So many physicians turned to chemotherapy in order to control the recurrence or those tumors which couldn’t be totally resected. Otsuka et al\textsuperscript{[15]} reported that the expressions of VEGF and VEGFR was related to each other and played important role in the formation of peritumoral brain edema. Nakada et al\textsuperscript{[11]} also reported that patients with VEGFR-2-positive meningiomas showed shorter progression-free survival, and sunitinib, as a tyrosine kinase inhibitor, showed positive effects in prolonging the progression-free survival in VEGFR positive patients, aiming to become a new type of chemotherapy\textsuperscript{[19]}. Due to limited number of patients who accepted chemotherapy, including Hydroxyurea, Temozolomide, Tamoxifen, Erlotinib, there were many researches which lacked medical evidence-based support\textsuperscript{[20]}.

Hence, it is important to investigate the molecular mechanisms of malignant behaviour and identify the potential therapeutic markers. In recent years, microarray technology at the genetic level has developed fast and widely used to identify the differential expressed genes (DEGs) and functional pathways which could help to illustrate the underlying mechanisms. Therefore, we compared gene expression profile between benign meningioma and normal meninges from the National Center of Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo) to identify DEGs and pathways, aiming to understand the molecular mechanisms underlying carcinogenesis and find potential therapeutic targets.
2. Materials and methods

Microarray data
The GEO database (http://www.ncbi.nlm.nih.gov/geo) was a public functional genomics of high throughout gene expression data. The gene expression dataset (GSE43290) was downloaded from GEO database (Affymatrix GPL96 platform, Affymatrix Human Genome U133A Array). The GSE43290 contained 33 benign meningoia tissue samples and 4 normal meninges tissue samples.

Identification of DEGs
The DEGs between benign meningoia and normal meninges samples were detected by GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r), and the adjusted P-value and \(|\text{LogFold Change(FC)}|\) were calculated. Probe sets without meaningful gene symbol and genes with more than one probes were eliminated. The \(|\text{LogFC}| \geq 2\) and adjusted P-value \(< 0.01\) were considered statistically significant.

GO and KEGG pathway enrichment analysis of DEGs
The Database for Annotation, Visualization and Integrated Discovery (DAVID) was an online gene analysis database which integrated bioinformatic data, biological pathways and provides functional annotations genes\(^{[21, 22]}\). The GO and KEGG pathway enrichment were performed by DAVID. The GO analyses which was a tool to annotate and analyze genes were classified into biological process (BP), cellular component (CC) and molecular function (MF)\(^{[21]}\). The KEGG pathway contained pathway maps for the molecular systems in both normal and perturbed states\(^{[24]}\). The gene counts \(\geq 10\) and FDR (adjusted P-value) \(< 0.05\) were considered statistically significant.

PPI network construction and module analysis
The Search Tool for the Retrieval of Interacting Gene database (STRING; http://string-db.org) was an online database to analyze interactions between proteins\(^{[25]}\). In this study, previous DEGs were mapped by STRING to evaluate the potential interactions of proteins with combined score \(> 0.9\). After that, PPI network was constructed and visualized by Cytoscape software (version 3.7.2) which was an open source bioinformatic software platform\(^{[26]}\). The plugin Molecular Complex Detection (MCODE, version 1.6) was used to find the intensively densely connected region based on topology\(^{[27]}\). The most significant network was detected by MCODE with following criteria: degree cutoff \(= 2\), node score cutoff \(= 0.2\), k-core \(= 2\), max depth \(= 100\).

Identification and analysis of hub genes
The plugin CytoHubba which provided 11 topological analysis methods of Cytoscape was being used to rank node in previous PPI network\(^{[28]}\). In this study, the top 10 genes were ranked by Cytohubba with Degree, the maximal clique centrality (MCC), maximum neighborhood component (MNC) and edge percolated component (EPC). The overlapping genes were considered as hub genes and further explored the
GO and KEGG pathways using Enrichr\cite{29}. The adjusted P-value<0.01 was considered statistically significant. We further downloaded and analyzed GEO dataset (GSE16581) by R software (version 4.0.1), illuminating the relationship between the expression of hub genes and clinical factors, including age and recurrence.

3. Results

Identification of DEGs
With the criteria $|\text{LogFC}| \geq 2$ and adjust P-value<0.01, a total of 358 DEGs were identified respectively, consisting of 15 upregulated genes and 343 downregulated genes between normal meninges and benign meningiomas, as shown in figure 1.

![Figure 1. Differential expression of data among two datasets.](image)

Note: The red points represent upregulated genes with $|\text{LogFC}| \geq 2$ and adjust P-value<0.01. The green points represent downregulated genes with $|\text{LogFC}| \geq 2$ and adjust P-value<0.01. The black points represent genes with no statistically significance.

GO and KEGG pathway enrichment of DEGs
The GO function and KEGG pathway analysis of DEGs were performed by DAVID. GO function analysis showed that changes in biological process (BP) were mainly enriched in extracellular matrix organization, inflammatory response, cell adhesion, regulation of blood pressure. Changes in cellular components (CC) were mainly enriched in extracellular space, extracellular region, axonextracellular matrix. Changes in molecular function (MF) were mainly enriched in integrin binding. The KEGG pathways showed that DEGs mainly enriched in Malaria, Focal adhesion (Table 1, Figure 2).

![Table 1. Significantly enriched GO terms and KEGG pathways of DEGs](image)

| Category | Term Description | Count | FDR   |
|----------|------------------|-------|-------|
| BP       | GO:0030198 extracellular matrix organization | 22    | 5.28E-07 |
| BP       | GO:0006954 inflammatory response | 30    | 7.68E-07 |
| GO:0007155 | cell adhesion | 32 | 4.01E-06 |
| GO:0008217 | regulation of blood pressure | 11 | 8.98E-04 |
| GO:0001666 | response to hypoxia | 16 | 0.002754706 |
| GO:0001525 | angiogenesis | 18 | 0.003633709 |
| GO:0016337 | single organismal cell-cell adhesion | 12 | 0.008203143 |
| GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 15 | 0.016753029 |
| GO:0071347 | cellular response to interleukin-1 | 10 | 0.0174516 |
| GO:0032496 | response to lipopolysaccharide | 14 | 0.03835128 |
| GO:0005615 | extracellular space | 64 | 4.63E-09 |
| GO:0005576 | extracellular region | 61 | 1.02E-04 |
| GO:0030424 | axon | 18 | 1.00E-03 |
| GO:0031012 | extracellular matrix | 20 | 0.03230368 |
| GO:0048471 | perinuclear region of cytoplasm | 29 | 0.01529324 |
| GO:0009986 | cell surface | 26 | 0.031262473 |
| GO:0043209 | myelin sheath | 13 | 0.031929 |
| GO:0070062 | extracellular exosome | 81 | 0.032123168 |
| GO:0005178 | integrin binding | 11 | 0.037757175 |
| hsa05144 | Malaria | 10 | 0.002806854 |
| hsa04510 | Focal adhesion | 18 | 0.012479012 |

Note: BP, biological process; CC, cellular component; MF, molecular function; GO, gene ontology.

Figure 2. Significant pathways and enriched differential expressed genes.

**PPI network construction and module analysis**

The PPI network of EDGs were constructed by STRING and visualized by Cytoscape. A total of 341 nodes and 324 edges were involved in PPI network.
The most significant module was constructed by MCODE plugin (Figure 4), including 14 nodes and 91 edges.

Figure 3. Protein-protein network interaction constructed with differential expressed genes. Note: Red terms represent upregulated genes. Green terms represent downregulated genes.

Figure 4. Module analysis using MCODE: Node Score Cutoff: 0.2, Haircut: true, Fluff: false, K-Core: 2, Max. Depth from Seed: 100.

**Hub genes selection and analysis**

To further explore hub genes, the Cytohubba plugin were being used to rank the top 10 nodes in the above PPI network with four topological methods, including Degree, MCC, MNC and EPC (Table 2). A total of 5 overlapping genes were selected as hub genes and further explored the GO and KEGG pathways by Enrichr (Table 3). The clinical outcomes of hub genes were showed in figure 5 and 6.

| Category | Rank methods in Cytohubba |
|----------|---------------------------|
|          | MNC | MCC | EPC | Degree |
| gene symbol | CXCL8 | AGT | GPR183 | CXCL8 |
AGT  CXCL8  APLNR  AGT  CXCR4  CXCL12  CXCR4  PPBP  CXCL12  CXCR4  CXCL12JUN  CXCL2  PPBP  CXCL8  CXCL12  GPR183  CXCL2  CXCL2  CXCR4  APLNR  ADRA2AP2RY14  CXCL2  ADRA2A  S1PR1  IL6  GPR183  CCL19  IL6  P2RY14  APLNR  PPBP  S1PR1

Note:Bold genes were the overlapping hub genes in the top 10 ranked genes with four methods in the Cytohubba.MNC,maximum neighbourhood component. MCC,maximal clique centrality.EPC,edge percolated component.Degree,node connect degree.

Table 3.Hub genes further analysis by Enrichr

| Category               | Description                                | Adjusted P-value | Genes                                |
|------------------------|--------------------------------------------|------------------|--------------------------------------|
| BP                     | chemokine-mediated signaling pathway(GO:0070098) | 8.43E-04         | CXCL8;CXCL12;CXCL2                   |
| BP                     | positive regulation of leukocyte chemotaxis(GO:0002690) | 6.86E-04         | CXCL8;CXCL12;CXCL2                   |
| BP                     | second-messenger-mediated signaling (GO:0019932) | 4.80E-04         | CXCL8;CXCR4;AGT                      |
| BP                     | induction of positive chemotaxis(GO:0050930) | 0.002868053      | CXCL8;CXCL12                         |
| BP                     | positive regulation of positive chemotaxis(GO:0050927) | 0.006114914      | CXCL8;CXCL12                         |
| MF                     | CXCR chemokine receptor binding (GO:0045236) | 5.86E-06         | CXCL8;CXCL12;CXCL2                   |
| MF                     | chemokine activity (GO:0008009)             | 6.53E-05         | CXCL8;CXCL12;CXCL2                   |
| MF                     | chemokine receptor binding (GO:0042379)     | 5.28E-05         | CXCL8;CXCL12;CXCL2                   |
| MF                     | cytokine activity (GO:0005125)              | 0.001298787      | CXCL8;CXCL12;CXCL2                   |
| KEGG_PATHWAY           | Chemokine signaling pathway                 | 1.21E-05         | CXCL8;CXCL12;CXCR4;CXCL2             |
| KEGG_PATHWAY           | Cytokine-cytokine receptor interaction      | 3.48E-05         | CXCL8;CXCL12;CXCR4;CXCL2             |
| KEGG_PATHWAY           | NF-kappa B signaling pathway                | 1.06E-04         | CXCL8;CXCL12;CXCL2                   |
| KEGG_PATHWAY           | Pathways in cancer                         | 1.84E-04         | CXCL8;CXCL12;CXCR4;AGT               |
| KEGG_PATHWAY           | Human cytomegalovirus infection             | 8.51E-04         | CXCL8;CXCL12;CXCR4                   |
| KEGG_PATHWAY           | Intestinal immune network for IgA production | 0.002881915      | CXCL12;CXCR4                         |
| KEGG_PATHWAY           | Legionellosis                               | 0.003249738      | CXCL8;CXCL2                         |
| KEGG_PATHWAY           | Salmonella infection                        | 0.006977051      | CXCL8;CXCL2                         |
| KEGG_PATHWAY           | Rheumatoid arthritis                        | 0.006944943      | CXCL8;CXCL12                        |
| KEGG_PATHWAY           | IL-17 signaling pathway                     | 0.006528466      | CXCL8;CXCL2                         |
| KEGG_PATHWAY           | AGE-RAGE signaling pathway in diabetic complications | 0.006862441 | CXCL8;AGT                           |
| KEGG_PATHWAY           | Leukocyte transendothelial migration        | 0.007889946      | CXCL12;CXCR4                         |

Note:BP,biological process;MF,molecular function;GO, gene ontology.
Figure 5. The clinical relationship between expression of hub genes and age

Figure 6. The clinical relationship between expression of hub genes and age. Note: R0 represents no recurrence. R1 represents recurrence.

4. Discussion

The growth pattern of meningioma can’t be predicted precisely and need long-term follow-up. Complete resection may not be applied to every single type of meningiomas, but tumor location is strongly associated with different Simpson grade removal and there could be many serious functional impairment, such as vascular insults or the 9th through 12th nerve deficit in ventral foramen magnum meningiomas. Radiotherapy is regarded as supplementary post-operative
treatment but should be applied discreetly, because of radiation resistance or the potential malignant transformation \cite{17,30}. Because of lacking potential therapeutic targets, we can use few ways to control meningioma. Thus, it’s important to explore the molecular mechanisms of benign meningioma and find the potential chemotherapeutic targets.

Nowadays, microarray data and high-throughout sequence which detect millions of genes play an important role in finding potential targets for cancer diagnosis and treatment. In present study, microarray data GSE43290 downloaded from GEO database was further analyzed to identify the key genes which might contribute to the occurrence and development of benign meningioma. A total of 358 DEGs were identified respectively, consisting of 15 upregulated genes and 343 downregulated genes. GO enrichment analysis showed that DEGs were mainly enriched in extracellular matrix organization, inflammatory response, cell adhesion, extracellular space and integrin binding. The significant KEGG pathway of DEGs were malaria and cell adhesion. At last, the selected hub genes were AGT, CXCL8, CXCL2, CXCL12 and CXCR4.

AGT, also called angiotensinogen, was known as precursor of the renin-angiotensin system. The human AGT gene, which coded for a 485-amino acid protein, consisted of five exons and four introns. Mature AGT protein contained 452 amino acid residues, which consisted of des(Ang I) AGT and angiotensin I(Ang I), an inactive decapetide which is converted into Ang II \cite{37}. Local Ang II in tumor environment (TME) produced by hypoxia-lactate-chymase-dependent mechanism was involved in immune escape and mediating radioresistance in tumor cells \cite{36-38}. And augmented AGT and angiotensin-converting enzyme (ACE) released from apoptotic endothelial cells played a vital role in turning to Ang II to accelerate the progress of vascular remodeling \cite{38}. It was demonstrated that human AGT inhibits endothelial cell proliferation and angiogenesis in vivo, and prevents tumor sinusoids from remodeling and anterionalization, thus inhibits tumor progression \cite{40,41}. Sun et al \cite{42} also reported that high glucose promoted tumor proliferation by suppressing AGT expression. In this study, the downregulation of AGT represented that AGT expression decreased and the role of delaying tumor angiogenesis was weakened.

CXCL8, also known as chemokine (C-X-C motif) ligand 8, plays a very important role in tumor growth, invasion and metastases in an autocrine and paracrine manner \cite{43}. Some researches demonstrated that CXCL8 was associated with many types of tumors, such as glioblastoma, lung adenocarcinoma, hepatocellular carcinoma and colon cancer \cite{44-46}. Luo et al \cite{44} demonstrated that high gene expression levels of CXCL8 and VEGF was correlating with recurrent glioblastoma. Daniel et al \cite{47} showed that IL-8 was strongly associated with glioma formation and progression mediated by activator protein-1 (AP-1) and nuclear transcription factor-kappa (NF- κ B) site. Liu et al \cite{45} showed that CXCL8 was an independent unfavorable factor with recurrence free survival and overall survival in patients suffering from adenocarcinoma, and the human Dachshund homologue 1 (DACH1) was able to antagonize CXCL8 through AP-1 and NF- κ B. Shen et al \cite{46} reported that CXCL8 may induce tumor proliferation, invasiveness through induction of epithelial-mesenchymal
transition via the phosphatidylinositol 3-kinase (PI3K)/protein kinase B(AKT)/nuclear factor-κ B(NF-κ B) pathway. Researches demonstrated that human meningioma cells secreted specifically the CXC chemokine-8[48, 49]. In our study, the differential expression of CXCL8 between two datasets suggested it as a important target.

CXCL2, also known as chemokine (C-X-C motif) ligand 2, was a member of chemokine subfamily. Some researches demonstrated that CXCL2 was overexpressed in breast, hepatic, colon and bladder cancer[50-53]. Typically, Ding et al[51] reported that CXCL2 was downregulated in hepatocellular carcinoma. Overexpression of CXCL2 significantly emasculated HCC cell proliferation, and the overall survival rates of high CXCL2 expression group were significantly higher than group with low CXCL2 expression. In this study, we manifested that CXCL2 was downregulated in benign meningiomas other than normal meninges, which may not inhibit meningioma proliferation.

CXCL12, also known as chemokine (C-X-C motif) ligand 12 or stromal cell-derived factor-1(SDF-1), also was a member of chemokine subfamily, widely expressed in many tissues[54, 55]. CXCL12 was secreted by meningeal cells as a chemotactic factor attracting external granul cells and played important role in embryogenesis, including vascularization, neurodevelopment, and maintained hemostasis in mature brain system[56, 57]. CXCL12 regulated tumor cell adhesion with laminin, fibrinogen and endothelial cell, and removal of CXCL12 abolished the chemotactic effect entirely[58]. Du R et al[58] and Santiago B et al[59] reported that under hypoxic conditions, tumor cells or fibroblasts upregulated SDF-1 miRNA to facilitate angiogenesis. Some researches[60, 61] demonstrated that hypoxia could also significantly stimulate CXCR4 expression. CXCR4, also known as chemokine (C-X-C motif) ligand receptor 4, was a G protein-coupled receptor activating by CXCL12[62]. Zhang et al[63] reported that the expression of CXCR4 was positively correlated with CXCL12 expression, and the chemotactic effect of CXCL12 was modulated by controlling CXCR4 expression. Moreover, Hartmann et al[64] reported that CXCL12-induced integrin activation and CXCR4 co-operated in mediating adhesion and survival signals from the TME. CXCL12/CXCR4 axis was also involved in blood vessel growth and remodeling[65], and Hiratsuka et al[66] demonstrated that inhibition of both VEGF1 and CXCR4 signaling showed greater effects on tumor vascular density, growth and metastasis than inhibition of VEGF1 alone. So we could know that CXCL12/CXCR4 axis plays a crucial role in tumor formation, proliferation and metastasis, thus causing tumor formation and invasion[49, 64, 67, 68]. Mo et al[69] demonstrated that CXCL12/CXCR4 promoted neurofibromatosis 1-associated malignant peripheral nerve sheath tumor(MPNST) proliferation, which illustrated that high CXCR4 expression was correlated with poor survival. Zeng et al[70] reported that blockage of CXCL12/CXCR4 axis by plerixafor prolonged survival of tumor-bearing mice by immunosuppression in the TME. Cai et al[71] reported that plasminogen kringle 5 reduced nuclear HIF-1α accumulation and impaired HIF-1α DNA-binding and transactivation function, thus suppressing the expression of CXCL12/CXCR4 to inhibit the neovascularization and tumor growth.
In those hub genes, the expressions of CXCL2 and CXCL8 were correlated with age, which was divided into two groups with the limits of 60 years old. With more genes and more pathways involving in tumorigenesis, it could be explained why elder people were frequently found with meningoma. Meanwhile these two hub genes were correlated with tumor recurrence. But we need further evidence to prove the effects in cell and tissue level.

5. Conclusion

The present study intended to investigate the DEGs which involved in the mechanism of tumor generation, proliferation and invasion. A total of 358 DEGs and 5 hub genes were identified and two hub genes, CXCL8 and CXCL2, were found to be correlated with tumor recurrence. Thus we have more methods to handle those meningiomas which can’t be resected completely in the long run. But more studies are needed to illustrate the clinical significance of these genes in meningioma.

Abbreviations:
GEO: Gene Expression Omnibus
DEG: differential expressed genes
GO: gene ontology
KEGG: Kyoto Encyclopedia of Gene and Genomes
DAVID: Database for Annotation, Visualization and Integreted Discovery
PPI: protein-protein interaction
STRING: Search Tool for the Retrieval of Interacting Gene database
CNS: central nervous system
MRI: magnetic resonance imaging
TME: tumor microenvironment
AGT: angiotensinogen
CXCL8: chemokine (C-X-C motif) ligand 8
CXCL2: chemokine (C-X-C motif) ligand 2
CXCL12: chemokine (C-X-C motif) ligand 12
SDF-1: stromal cell-derived factor-1
CXCR4: chemokine (C-X-C motif) ligand receptor 4
MPNST: malignant peripheral nerve sheath tumor

Declarations:
Ethics approval and consent to participate: Not applicable.
Consent for publication: All the authors have read and approved the final version of manuscript and give consent.
Availability of data and materials: Not applicable.
Competing interests: The authors declare that they have no competing interests.
Funding: Not applicable.
Authors’ contributions: MC conceived the conception, MC and CS searched the literature, MC drafted the manuscript with help of JZ. YHW corrected the details and references. All authors read and approved the final manuscript.
Acknowledgements: Not applicable.

References:
[1] Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene, 2011, 30(20): 2333-2344.
[2] Whittle IR, Smith C, Navoo P. Meningiomas. Lancet 2004; 363: 1535-1543.
[3] Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol, 2016, 131(6): 803-820.
[4] Ostrom QT, Gittleman H, Farah P, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neuro Oncol, 2013, 15(suppl 2): i1-i56.
[5] Hale AT, Wang L, Strother MK. Differentiating meningioma grade by imaging features on magnetic resonance imaging. J Clin Neurosci, 2018; 48: 71-75.
[6] Sathirareuangchai S, Kakazu K, Tauchi-Nishi P, et al. Low grade intracranial meningioma presenting with pulmonary metastasis: Case report and literature review. Pathol Res Pract, 2019, 215(7): 152390.
[7] Clark VE, Ersön-Omay EZ, Serin A, et al. Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO. Science, 2013, 339(6123): 1077-1080.
[8] Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet, 1994; 6: 180-184.
[9] Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, et al. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. J Neurosurg, 2016, 124(1): 106-114.
[10] Balik V, Kourilova P, Sulla I, et al. Recurrence of surgically treated parasagittal meningiomas: a meta-analysis of risk factors. Acta Neurochir (Wien), 2020; 10.1007/s00701-020-04336-3.
[11] Nakada S, Sasagawa Y, Tachibana O, et al. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival. Brain Tumor Pathol, 2019, 36(1): 7-13.
[12] Soyuer S, Chang EL, Selel U, et al. Radiotherapy after surgery for benign cerebral meningioma. Radiother Oncol, 2004, 71(1): 85-90.
[13] Condra KS, Buatti JM, Mendenhall WM, et al. Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys, 1997; 39: 427-436.
[14] Goldsmith BJ, Wara WM, Wilson CB. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg, 1994; 80: 195-201.
[15] Wenkel E, Thornton A F, Finkelstein D, et al. Benign meningioma: Partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. Int J Radiat Oncol Biol Phys, 2000, 48(5): 1363-1370.
[16] Braganza M Z, Kitahara C M, Berrington D G A, et al. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol,2012,14(11):1316-1324.
[17] Pollock B E, Link M J, Stafford S L, et al. The Risk of Radiation-Induced Tumors or Malignant Transformation After Single-Fraction Intracranial Radiosurgery: Results Based on a 25-Year Experience. Int J Radiat Oncol Biol Phys,2017,97(5):919-923.
[18] Otsuka S, Tamiya T, Ono Y, et al. The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neurooncol,2004,70(3):349-357.
[19] Kaley T J, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol,2015,17(1):116-121.
[20] Kaley T, Barani I, Chamberlain M, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncology,2014,16(6):829-840.
[21] Huang D W, Sherman B T, Tan Q, et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol,2007,8(9):R183.
[22] Huang da W, Sherman BT. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
[23] Ashburner M, Ball C A, Blake J A, et al. Gene Ontology: tool for the unification of biology. Nat Genet,2000,25(1):25-29.
[24] Kanchisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res,2010;38:D355-60.
[25] Szklarczyk D, Gable A L, Lyon D, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res,2019,47(D1):D607-D613.
[26] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-2504.
[27] Bandettini W P, Killman P, Mancini C, et al. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson,2012,14:83.
[28] Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol,2014;8 Suppl 4:S11.
[29] Kuleshov M V, Jones M R, Rouillard A D, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res,2016,44(W1):W90-W97.
[30] Hashiba T, Hashimoto N, Izumoto S, et al. Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas. J Neurosurg,2009,110(4):675-684.
[31] Arnautović KI, Al-Mefty O. Ventral foramen magnum meningiomas. J Neurosurg
2000;92:71-80.

[32] Talacchi A, Biroli A, Soda C, et al. Surgical management of ventral and ventrolateral foramen magnum meningiomas: report on a 64-case series and review of the literature. Neurosurg Rev,2012;35,359-368.

[33] Chen S, Lin C, Liao C, et al. The pretemporal trans-cavernous trans-Meckel’s trans-tentorial trans-petrosal approach: a combo skill in treating skull base meningiomas.J Neurooncol,2020,146(3):407-416.

[34] Kaley T, Barani I, Chamberlain M, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.Neuro Oncol,2014;16,829-840.

[35] Corvol P. Molecular genetics of human hypertension: role of angiotensinogen.Endocr Rev,1997;18:662-677.

[36] Xie G, Cheng T, Lin J, et al. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy. J Immunother Cancer,2018,6(1):88.

[37] George A J, Thomas W G, Hannan R D. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer,2010,10(11):745-759.

[38] Xie G, Liu Y, Yao Q, et al. Hypoxia-induced angiotensin II by the lactate-chymase-dependent mechanism mediates radioresistance of hypoxic tumor cells. Sci Rep,2017;7:42396.

[39] Wu S J, Soulez M, Yang Y H, et al. Local Augmented Angiotensinogen Secreted from Apoptotic Vascular Endothelial Cells Is a Vital Mediator of Vascular Remodelling.PLoS One,2015,10(7):e132583.

[40] Célérier J, Cruz A, Lamandé N, et al. Angiotensinogen and Its Cleaved Derivatives Inhibit Angiogenesis. Hypertension,2002,39(2):224-228.

[41] Vincent F, Bonnin P, Clemessy M, et al. Angiotensinogen Delays Angiogenesis and Tumor Growth of Hepatocarcinoma in Transgenic Mice. Cancer Res,2009,69(7):2853-2860.

[42] Sun S, Sun Y, Rong X, et al. High glucose promotes breast cancer proliferation and metastasis by impairing angiotensinogen expression. Biosci Rep,2019,39(6).

[43] Liu Q, Li A, Tian Y, et al. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev,2016;31:61-71.

[44] Luo X, Xu S, Zhong Y, et al. High gene expression levels of VEGFA and CXCL8 in the peritumoral brain zone are associated with the recurrence of glioblastoma: A bioinformatics analysis. Oncol Lett,2019,18(6):6171-6179.

[45] Liu Q, Li A, Yu S, et al. DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis. J Hematol Oncol,2018;11:53.

[46] Shen T, Yang Z, Cheng X, et al. CXCL8 induces epithelial-mesenchymal transition in colon cancer cells via the PI3K/Akt/NF-κB signaling pathway. Oncol Rep,2017;37:2095-2100.

[47] Brat DJ, Bellail AC. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol,2005;7:122-133.

[48] Christodoulides M, Makepeace B L, Partridge K A, et al. Interaction of Neisseria meningitidis with Human Meningeal Cells Induces the Secretion of a Distinct Group of Chemotactic, Proinflammatory, and Growth-Factor Cytokines. Infect
Barbieri F, Bajetto A, Porcile C, et al. CXC Receptor and Chemokine Expression in Human Meningioma: SDF1/CXCR4 Signaling Activates ERK1/2 and Stimulates Meningioma Cell Proliferation. Ann N Y Acad Sci,2006,1090(1):332-343.

Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell, 2012; 150: 165-178.

Ding J, Xu K, Zhang J, et al. Overexpression of CXCL2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma. BMB Rep, 2018; 51: 630-635.

Kollmar O, Scheuer C, Menger MD. Macrophage inflammatory protein-2 promotes angiogenesis, cell migration, and tumor growth in hepatic metastasis. Ann Surg Oncol, 2006; 13: 263-275.

Zhang H, Ye YL, Li MX, et al. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer. Oncogene, 2017; 36: 2095-2104.

Timotijević G, Mostarica Stojković M. CXCL12: role in neuroinflammation. Int J Biochem Cell Biol, 2012; 44: 838-841.

Meng W, Xue S, Chen Y. The role of CXCL12 in tumor microenvironment. Gene, 2018; 641: 105-110.

Li M, Ransohoff R. Multiple roles of chemokine CXCL12 in the central nervous system: A migration from immunology to neurobiology. Prog Neurobiol, 2008; 84(2): 116-131.

Reiss K, Mentlein R, Sievers J, et al. Stromal cell-derived factor 1 is secreted by meningeal cells and acts as chemotactic factor on neuronal stem cells of the cerebellar external granular layer. Neuroscience, 2002; 115(1): 295-305.

Du R, Lu K V, Petritsch C, et al. HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion. Cancer Cell, 2008; 13(3): 206-220.

Santiago B, Calonge E, Rey M J D, et al. CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts. Cytokine, 2011; 53(2): 184-190.

Cai WB, Zhang Y, Cheng R, et al. Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway. PLoS One, 2012; 7(12): e53152.

Dai T, Hu Y, Zheng H. Hypoxia increases expression of CXC chemokine receptor 4 via activation of PI3K/Akt leading to enhanced migration of endothelial progenitor cells. Eur Rev Med Pharmacol Sci, 2017; 21(8): 1820-1827.

Malik R, Marchese A. Arrestin-2 interacts with the endosomal sorting complex required for transport machinery to modulate endosomal sorting of CXCR4. Mol Biol Cell, 2010; 21(14): 2529-2541.

Zhang C, Chang F Y, Zhou W Y, et al. The prognostic value of C-X-C motif chemokine receptor 4 in patients with sporadic malignant peripheral nerve sheath tumors. Chin J Cancer, 2017; 36(1): 80.

Hartmann T N, Burger J A, Glodek A, et al. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small
cell lung cancer (SCLC) cells. Oncogene, 2005, 24(27): 4462-4471.

[65] Dimova I, Karthik S, Makanya A, et al. SDF-1/CXCR4 signalling is involved in blood vessel growth and remodelling by intussusception. J Cell Mol Med, 2019, 23(6): 3916-3926.

[66] Hiratsuka S, Duda D G, Huang Y, et al. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad Sci U S A, 2011, 108(1): 302-307.

[67] Yang P, Hu Y, Zhou Q. The CXCL12-CXCR4 signaling axis plays a key role in cancer metastasis and is a potential target for developing novel therapeutics against metastatic cancer. Curr Med Chem. 2019; 10.2174/0929867326666191113113110.

[68] Yin X, Liu Z, Zhu P, et al. CXCL12/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K/AKT signal pathway. J Cell Biochem, 2019, 120(6): 9724-9736.

[69] Mo W, Chen J, Patel A, et al. CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell, 2013; 152(5): 1077-1090.

[70] Zeng Y, Li B, Liang Y, et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J, 2019, 33(5): 6596-6608.